Jussi Jaakko Saukkonen, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antitubercular Agents | 20 | 2019 | 1320 | 1.390 |
Why?
|
| Tuberculosis | 13 | 2016 | 1912 | 0.980 |
Why?
|
| Latent Tuberculosis | 6 | 2019 | 225 | 0.870 |
Why?
|
| Thorax | 1 | 2023 | 547 | 0.730 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 632 | 0.660 |
Why?
|
| Pneumonia | 3 | 2023 | 2133 | 0.520 |
Why?
|
| Alcoholism | 2 | 2023 | 1906 | 0.470 |
Why?
|
| Isoniazid | 6 | 2019 | 274 | 0.430 |
Why?
|
| Rifampin | 5 | 2019 | 315 | 0.400 |
Why?
|
| Liver Function Tests | 3 | 2012 | 528 | 0.390 |
Why?
|
| Heart | 1 | 2023 | 4467 | 0.360 |
Why?
|
| Pyrazinamide | 3 | 2004 | 54 | 0.360 |
Why?
|
| Mycobacterium tuberculosis | 9 | 2016 | 1832 | 0.350 |
Why?
|
| Immunoassay | 1 | 2011 | 752 | 0.310 |
Why?
|
| Refusal to Participate | 2 | 2019 | 24 | 0.290 |
Why?
|
| Interferon-gamma | 4 | 2011 | 3206 | 0.270 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1738 | 0.240 |
Why?
|
| Urban Population | 2 | 2011 | 2021 | 0.240 |
Why?
|
| Phenobarbital | 1 | 2023 | 193 | 0.220 |
Why?
|
| Medication Adherence | 4 | 2017 | 2063 | 0.220 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 2278 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2012 | 3022 | 0.190 |
Why?
|
| Chemokines, CC | 1 | 2002 | 291 | 0.190 |
Why?
|
| Benzodiazepines | 2 | 2023 | 1101 | 0.190 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2015 | 810 | 0.190 |
Why?
|
| Receptors, Fibronectin | 1 | 1999 | 39 | 0.180 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1999 | 143 | 0.170 |
Why?
|
| Directly Observed Therapy | 2 | 2017 | 137 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 3923 | 0.150 |
Why?
|
| Community-Acquired Infections | 1 | 2021 | 465 | 0.150 |
Why?
|
| Emergencies | 1 | 2023 | 1170 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 1999 | 4479 | 0.140 |
Why?
|
| Respiratory Insufficiency | 1 | 2004 | 1199 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2006 | 2616 | 0.130 |
Why?
|
| Oxazolidinones | 2 | 2012 | 96 | 0.130 |
Why?
|
| Esophageal Stenosis | 1 | 1996 | 195 | 0.130 |
Why?
|
| Integrins | 1 | 1999 | 846 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7279 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 7913 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2006 | 3743 | 0.120 |
Why?
|
| Receptors, Cytokine | 1 | 2015 | 261 | 0.120 |
Why?
|
| Th1 Cells | 1 | 1999 | 1057 | 0.120 |
Why?
|
| Patient Selection | 2 | 2019 | 4215 | 0.120 |
Why?
|
| Acetamides | 2 | 2012 | 249 | 0.120 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2012 | 912 | 0.120 |
Why?
|
| Cytokines | 2 | 2015 | 7322 | 0.110 |
Why?
|
| Bronchi | 1 | 1996 | 840 | 0.110 |
Why?
|
| Liver | 3 | 2006 | 7474 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2007 | 4420 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 2011 | 214 | 0.090 |
Why?
|
| Cough | 1 | 2013 | 555 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 9959 | 0.090 |
Why?
|
| HIV Infections | 6 | 2016 | 16718 | 0.080 |
Why?
|
| Humans | 38 | 2023 | 744343 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 4258 | 0.080 |
Why?
|
| Chemokine CCL4 | 3 | 2002 | 128 | 0.080 |
Why?
|
| Macrophage Inflammatory Proteins | 3 | 2002 | 122 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2011 | 694 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 6489 | 0.070 |
Why?
|
| Patient Compliance | 2 | 2006 | 2684 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2013 | 2618 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1997 | 4386 | 0.060 |
Why?
|
| Chemokine CCL5 | 2 | 2002 | 209 | 0.060 |
Why?
|
| Stents | 1 | 1996 | 3280 | 0.060 |
Why?
|
| Bronchial Spasm | 1 | 2004 | 73 | 0.060 |
Why?
|
| Patient Preference | 1 | 2011 | 890 | 0.060 |
Why?
|
| Amphetamines | 1 | 2004 | 148 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2004 | 188 | 0.060 |
Why?
|
| Solvents | 1 | 2004 | 302 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 3 | 1997 | 1838 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 421 | 0.050 |
Why?
|
| Risk Factors | 6 | 2019 | 72290 | 0.050 |
Why?
|
| Narcotics | 1 | 2004 | 343 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2002 | 104 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2006 | 764 | 0.050 |
Why?
|
| Soybean Proteins | 1 | 2001 | 61 | 0.050 |
Why?
|
| Family Practice | 1 | 2004 | 516 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 1105 | 0.050 |
Why?
|
| Pulmonary Edema | 1 | 2004 | 414 | 0.050 |
Why?
|
| Male | 19 | 2019 | 350118 | 0.050 |
Why?
|
| Pneumothorax | 1 | 2004 | 379 | 0.050 |
Why?
|
| Macrophages | 2 | 2007 | 5655 | 0.050 |
Why?
|
| Prospective Studies | 6 | 2012 | 53288 | 0.050 |
Why?
|
| HIV | 1 | 2007 | 1604 | 0.050 |
Why?
|
| Macrophages, Alveolar | 1 | 2002 | 407 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15076 | 0.040 |
Why?
|
| Female | 18 | 2019 | 380194 | 0.040 |
Why?
|
| Antigens, Protozoan | 1 | 2001 | 322 | 0.040 |
Why?
|
| Integrin alpha4beta1 | 1 | 1999 | 121 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 9849 | 0.040 |
Why?
|
| Interleukin-16 | 1 | 1998 | 33 | 0.040 |
Why?
|
| Cocaine | 1 | 2004 | 1007 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2001 | 558 | 0.040 |
Why?
|
| Adult | 18 | 2019 | 214055 | 0.040 |
Why?
|
| Boston | 1 | 2011 | 9313 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1999 | 573 | 0.040 |
Why?
|
| Cannabis | 1 | 2004 | 439 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 1997 | 120 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 77449 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2004 | 961 | 0.040 |
Why?
|
| Histamine | 1 | 1998 | 507 | 0.040 |
Why?
|
| Bronchial Neoplasms | 1 | 1996 | 112 | 0.030 |
Why?
|
| Canada | 2 | 2016 | 2065 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 1998 | 768 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 841 | 0.030 |
Why?
|
| Fibronectins | 1 | 1999 | 726 | 0.030 |
Why?
|
| Lung | 1 | 1993 | 9856 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2015 | 63114 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2015 | 264 | 0.030 |
Why?
|
| Endothelium, Vascular | 2 | 1997 | 4456 | 0.030 |
Why?
|
| Chemokines | 1 | 1998 | 970 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 1999 | 1200 | 0.030 |
Why?
|
| Acute Disease | 1 | 2004 | 7149 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 1997 | 3144 | 0.030 |
Why?
|
| Cell Count | 1 | 1997 | 1856 | 0.030 |
Why?
|
| Massachusetts | 1 | 2006 | 8663 | 0.030 |
Why?
|
| Public Health | 2 | 2016 | 2603 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2011 | 23338 | 0.030 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2007 | 354 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1999 | 1904 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 2959 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2001 | 1703 | 0.030 |
Why?
|
| Biological Availability | 1 | 2013 | 397 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 12245 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 2866 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 1850 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2007 | 565 | 0.020 |
Why?
|
| Critical Care | 1 | 2004 | 2647 | 0.020 |
Why?
|
| Apoptosis | 1 | 2007 | 9727 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 1836 | 0.020 |
Why?
|
| Sputum | 1 | 2012 | 476 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 3768 | 0.020 |
Why?
|
| Uganda | 1 | 2015 | 1243 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12354 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2012 | 421 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1998 | 2617 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1993 | 1588 | 0.020 |
Why?
|
| Middle Aged | 8 | 2013 | 213383 | 0.020 |
Why?
|
| Young Adult | 4 | 2019 | 56430 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2012 | 12026 | 0.020 |
Why?
|
| Cell Movement | 2 | 1997 | 5217 | 0.020 |
Why?
|
| Incidence | 1 | 2006 | 20947 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3870 | 0.020 |
Why?
|
| U937 Cells | 1 | 2007 | 268 | 0.020 |
Why?
|
| Recurrence | 2 | 2013 | 8340 | 0.020 |
Why?
|
| South Africa | 1 | 2012 | 1731 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 1676 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 956 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1996 | 1583 | 0.020 |
Why?
|
| Biological Specimen Banks | 1 | 2011 | 711 | 0.020 |
Why?
|
| United States | 5 | 2016 | 69872 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1477 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 443 | 0.020 |
Why?
|
| Biliary Tract Diseases | 1 | 1967 | 161 | 0.020 |
Why?
|
| Prognosis | 1 | 2006 | 29063 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1967 | 418 | 0.020 |
Why?
|
| Adolescent | 5 | 2019 | 85781 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1967 | 592 | 0.010 |
Why?
|
| Time Factors | 2 | 2017 | 40075 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2012 | 2682 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3778 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 57776 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1993 | 5974 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10397 | 0.010 |
Why?
|
| Aged | 6 | 2013 | 163280 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2007 | 1539 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2019 | 41006 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 7023 | 0.010 |
Why?
|
| Child | 3 | 2019 | 77709 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2001 | 154 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 4034 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1997 | 11483 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13408 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2373 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8324 | 0.010 |
Why?
|
| Asthma | 1 | 1998 | 6011 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2007 | 2499 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 1998 | 83 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2007 | 2969 | 0.010 |
Why?
|
| Cost Savings | 1 | 2004 | 926 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 7785 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 1998 | 227 | 0.010 |
Why?
|
| Age Factors | 1 | 2015 | 18370 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2001 | 592 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 1681 | 0.010 |
Why?
|
| Research Design | 1 | 2012 | 5987 | 0.010 |
Why?
|
| Methylamines | 1 | 1977 | 123 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2050 | 0.010 |
Why?
|
| Breath Tests | 1 | 1977 | 280 | 0.010 |
Why?
|
| Uremia | 1 | 1977 | 201 | 0.010 |
Why?
|
| Protozoan Proteins | 1 | 2001 | 827 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1998 | 675 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39050 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15540 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1995 | 290 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 4933 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 2216 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2001 | 2132 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 13102 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2001 | 2938 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 5391 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 1880 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 12951 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 1995 | 1348 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1995 | 1821 | 0.000 |
Why?
|
| Sulfobromophthalein | 1 | 1967 | 9 | 0.000 |
Why?
|
| Cell Line | 1 | 2001 | 15997 | 0.000 |
Why?
|
| Clinical Enzyme Tests | 1 | 1967 | 115 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2001 | 14557 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2006 | 25625 | 0.000 |
Why?
|
| Genital Diseases, Female | 1 | 1967 | 197 | 0.000 |
Why?
|
| Cholecystectomy | 1 | 1967 | 395 | 0.000 |
Why?
|
| Infant | 1 | 2006 | 35136 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 9648 | 0.000 |
Why?
|
| Gastrectomy | 1 | 1967 | 663 | 0.000 |
Why?
|
| Muscles | 1 | 1967 | 1614 | 0.000 |
Why?
|
| Extremities | 1 | 1967 | 865 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1995 | 9274 | 0.000 |
Why?
|
| Dimethylamines | 1 | 1977 | 7 | 0.000 |
Why?
|
| Chromatography, Gas | 1 | 1977 | 156 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 81183 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1967 | 12959 | 0.000 |
Why?
|
| Mass Spectrometry | 1 | 1977 | 2203 | 0.000 |
Why?
|
| Animals | 1 | 2001 | 168757 | 0.000 |
Why?
|
| Renal Dialysis | 1 | 1977 | 1786 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1967 | 11727 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1967 | 15295 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1977 | 7181 | 0.000 |
Why?
|